Pharmaceutical industry becomes geopolitical battleground as US threatens tariffs • FRANCE 24

Key Concepts

• Pharmaceutical Sovereignty: Policies aimed at prioritizing domestic drug manufacturing through trade pressure and tariffs.
• Unsustainable Business Model: The critique that the current pharmaceutical industry relies on unaffordable pricing rather than value-based innovation.
• International Reference Pricing: The practice of using geopolitical leverage to force other nations to pay higher prices for drugs to subsidize US market costs.
• R&D Investment: The argument that domestic drug prices do not dictate the location of Research and Development, as these investments target global markets.
• Weight-Loss Drugs (GLP-1 agonists): A rapidly growing sector involving medications like Wegovy and Mounjaro, now being integrated into public health reimbursement schemes.

---

1. The Geopolitics of Pharmaceutical Pricing

The pharmaceutical industry is increasingly becoming a tool of geopolitical strategy. The US administration has utilized the threat of tariffs to pressure other nations into accepting higher prices for US-manufactured drugs.

• The US Pricing Crisis: A 2024 study indicates that prescription drug prices in the US are nearly three times higher than in 33 other advanced economies, and over four times higher for brand-name drugs.
• The "Most Favored Nation" Argument: While the US government claims recent negotiations have secured the "lowest prices" for Americans, experts like Karl Claxton argue this is a misrepresentation. Instead, the US is leveraging its geopolitical power to force other countries to pay higher prices, effectively exporting the US healthcare cost crisis globally.

2. The UK-US Trade Deal: A Case Study

Claxton highlights a specific agreement between the UK and US as a cautionary tale for other nations.

• The Mechanism: The UK agreed to pay more for US-made drugs in exchange for avoiding tariffs on British pharmaceutical exports to the US.
• The Economic Flaw: Claxton notes that within three years, the additional costs incurred by the UK under this deal will exceed the total value of all its pharmaceutical and medical device exports to the US.
• Investment Fallacy: The argument that higher domestic prices attract R&D investment is dismissed; R&D is a global endeavor, and local price hikes do not incentivize local innovation.

3. Global Manufacturing and Regulatory Standards

There is a growing reliance on India and China for pharmaceutical ingredients and manufacturing.

• Regulatory Perspective: Contrary to concerns about quality, Claxton argues that Western regulatory standards have been "hollowed out," leading to expensive drugs with limited evidence of long-term benefit.
• Future Outlook: He suggests that the growth of the biotech sectors in China and India may actually provide a solution to the current unsustainable, high-cost model by offering more affordable alternatives.

4. The Rise of Weight-Loss Medications

France has become the first EU country to reimburse treatments like Wegovy and Mounjaro for patients with morbid obesity (BMI ≥ 40, or ≥ 35 with comorbidities).

• Economic Rationale: The French government expects to spend 100 million euros annually on this, hoping that reducing severe obesity will lower long-term costs associated with heart health and other complications.
• Access Concerns: A significant risk identified is the "rationing" of these drugs based on wealth. Experts emphasize the need for proper long-term evidence, the eventual introduction of cheaper generics, and ensuring that those with the greatest medical need—not just those who can afford the monthly co-pay—receive access.

5. Synthesis and Conclusion

The pharmaceutical industry is currently built on a "profoundly unsustainable" model that prioritizes high prices over value-based innovation. The shift toward using geopolitical and trade pressure to maintain these prices is viewed as a "disaster" that threatens global healthcare systems.

Main Takeaways:

• Systemic Reform Needed: The industry must pivot toward innovations that offer genuine health benefits and can be produced at affordable prices post-patent.
• AI Integration: The use of AI in drug discovery is a promising milestone, but its benefits will only be realized if international pricing structures are fixed.
• Value-Based Healthcare: Future success depends on moving away from price-gouging and toward a model where drug prices reflect the actual affordability and economic capacity of different healthcare systems.

"The reality is that the rest of the world is already paying much more than its fair share of the value of the innovations that are being brought forward, and US citizens are also paying much more than they can afford." — Karl Claxton, University of York